Document Detail


Cognitive outcomes after sertaline treatment in patients with depression of Alzheimer disease.
MedLine Citation:
PMID:  23032478     Owner:  NLM     Status:  MEDLINE    
Abstract/OtherAbstract:
OBJECTIVES: Although many depressed patients with Alzheimer disease (AD) are treated with antidepressants, the effect of such treatment on cognitive performance in these patients is not known. The authors report cognitive outcomes in patients with depression of AD (dAD) after a 24-week trial of sertraline or placebo.
DESIGN: Placebo-controlled, randomized, double-blind trial.
SETTING: Outpatient memory clinics at five academic medical centers in the United States.
PARTICIPANTS: A total of 131 patients with dAD (60 men) and Mini-Mental State Examination scores of 10-26.
INTERVENTION: Sertraline (n = 67), target dose of 100 mg daily or matching placebo (n = 64). Caregivers received standardized psychosocial intervention throughout the trial.
MEASUREMENTS: Mini-Mental State Examination, cognitive subscale of the Alzheimer's Disease Assessment Scale, letter fluency, backward digit span, Symbol Digit Modalities Test, and Finger Tapping Test, administered at baseline, and 8, 16, and 24 weeks following baseline.
RESULTS: A series of linear models indicated no effect of treatment or of depression remission on cognitive test performance at 24 weeks. Regardless of treatment condition, very little change in cognitive test performance was noted in general.
CONCLUSIONS: Treatment with sertraline in patients with dAD is not associated with greater improvement in cognition at week 24 than treatment with placebo.
Authors:
Cynthia A Munro; Crystal Flynn Longmire; Lea T Drye; Barbara K Martin; Constantine E Frangakis; Curtis L Meinert; Jacobo E Mintzer; Anton P Porsteinsson; Peter V Rabins; Paul B Rosenberg; Lon S Schneider; Daniel Weintraub; Constantine G Lyketsos;
Related Documents :
23137678 - Rumination, depressive symptoms and awareness of illness in schizophrenia.
23206378 - Is there a bidirectional relationship between depressive symptoms and cognitive ability...
21889248 - Increased spreading activation in depression.
23302978 - Predictors of cognitive recovery after cardiac surgery.
8580388 - Acute effects of fluoxetine versus placebo on functional health and well-being in late-...
21932428 - Respiratory protective equipment, mask use, and respiratory outcomes among world trade ...
Publication Detail:
Type:  Journal Article; Multicenter Study; Randomized Controlled Trial; Research Support, N.I.H., Extramural; Research Support, Non-U.S. Gov't    
Journal Detail:
Title:  The American journal of geriatric psychiatry : official journal of the American Association for Geriatric Psychiatry     Volume:  20     ISSN:  1545-7214     ISO Abbreviation:  Am J Geriatr Psychiatry     Publication Date:  2012 Dec 
Date Detail:
Created Date:  2012-11-27     Completed Date:  2013-05-06     Revised Date:  2013-12-23    
Medline Journal Info:
Nlm Unique ID:  9309609     Medline TA:  Am J Geriatr Psychiatry     Country:  United States    
Other Details:
Languages:  eng     Pagination:  1036-44     Citation Subset:  IM    
Export Citation:
APA/MLA Format     Download EndNote     Download BibTex
MeSH Terms
Descriptor/Qualifier:
Aged
Aged, 80 and over
Alzheimer Disease / drug therapy,  psychology*
Ambulatory Care Facilities
Antidepressive Agents / pharmacology,  therapeutic use*
Cognition / drug effects*
Depressive Disorder / drug therapy*,  etiology
Double-Blind Method
Female
Humans
Male
Neuropsychological Tests
Sertraline / pharmacology,  therapeutic use*
Treatment Outcome
Grant Support
ID/Acronym/Agency:
1U01MH066136/MH/NIMH NIH HHS; 1U01MH066174/MH/NIMH NIH HHS; 1U01MH066175/MH/NIMH NIH HHS; 1U01MH066176/MH/NIMH NIH HHS; 1U01MH066177/MH/NIMH NIH HHS; 1U01MH068014/MH/NIMH NIH HHS; P50 AG005146/AG/NIA NIH HHS; U01 MH066136/MH/NIMH NIH HHS
Chemical
Reg. No./Substance:
0/Antidepressive Agents; QUC7NX6WMB/Sertraline
Investigator
Investigator/Affiliation:
Constantine Lyketsos / ; Barbara Martin / ; George Niederehe / ; Paul Rosenberg / ; Jacobo Mintzer / ; Daniel Weintraub / ; Anton P Porsteinsson / ; Lon Schneider / ; Anne Shanklin Casper / ; Lea Drye / ; Curtis Meinert / ; Crystal Evans / ; Cynthia Munro / ; Peter Rabins / ; Constantine Lyketsos / ; Crystal Evans / ; Cynthia Munro / ; Peter Rabins / ; Krissi Boehmer / ; Adrian Mosely / ; Dimitrios Avramopoulos / ; Curtis Meinert / ; Barbara Martin / ; Lea Drye / ; Constantine Frangakis / ; Anne Shanklin Casper / ; Vijay Vaidya / ; Jill Meinert / ; George Niederehe / ; Jovier Evans / ; Joanna Chisar / ; Louise Ritz / ; Elizabeth Zachariah / ; Paul Rosenberg / ; Ann Morrison / ; Crystal Evans / ; Pramit Rastogi / ; Krissi Boehner / ; Chiadi Onyike / ; Jacobo Mintzer / ; Crystal Longmire / ; Warachal E Faison / ; Martie Hatchell / ; Marilyn Stuckey / ; Daniel Weintraub / ; Ira Katz / ; Trisha Stump / ; Joel Streim / ; Suzanne DiFilippo / ; Kate O'Neill / ; Anton P Porsteinsson / ; Bonnie Goldstein / ; Jeanne LaFountain / ; Colleen McCallum / ; Laura Jakimovich / ; Kim Martin / ; Margaret McGrath / ; Kelly M Cosman / ; Lon S Schneider / ; Sonia Pawluczyk / ; Karen Dagerman / ; Randall Sanabria / ; Liberty Teodoro / ; Yanli Wang / ; Ju Zhang /
Comments/Corrections

From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine


Previous Document:  Alternative Decision-Makers' Perspectives on Assent and Dissent for Dementia Research.
Next Document:  Cognitive change checklist: psychometric characteristics in community-dwelling older adults.